CA Sumit Mangla
@sumit_7320
Delhi
7+ Years of experience
SEBI Registration INH000028626WELCOME TO TRADING WITH CA SUMIT MANGLA - SEBI REGISTERED RESEARCH ANALYST Registration No. INH000028626 We provide professional trading calls across multiple segments: 1. Indices – Intraday Option Buying & Selling 2. F&O Stocks – Intraday Futures, Intraday Option Selling & BTST Futures 3. Cash Stocks – Intraday & ... Read more
Trade Ideas
38
Opinions
27
Followers
122
Expertise
Quantitative
Growth
Technical
Index Strategies
Market Commentary
Futures & Options
Technical Analysis
Trade Facts
Total Trades
0
Missed Trades
0
Profit Trades
0
0%Accuracy
Ask me Anything
Got a question? Ask me and I will answer it. Stay curious, stay hungry!
Posts
shared an insight ⚡️ 9 hours ago
INDUSINDBK
Guides for Market-Aligned Growth with 1% Exit ROA in FY27INDUSINDBK
has outlined a measured growth strategy for FY27, aligning its expansion with the broader market while targeting an exit Return on Assets (ROA) of 1%.
Management expects Net Interest Margin (NIM) to face pressure in Q2 FY27 before recovering in the second half. While NIM will be a smaller contributor to ROA in the near term, it remains a significant long-term opportunity.
Over the next three years, the bank plans to reduce its overall wholesale mix, with faster growth in SME, mid-corporate, large corporate, and other retail segments. Microfinance is set for meaningful traction from Q2 FY27, supported by further slippage reduction. Vehicle finance disbursements (excluding two-wheelers) are expected to accelerate.
In consumer banking, slippages are likely to decline meaningfully as the bank reaches the tail end of elevated risk from personal loans and credit cards, paving the way for a return to growth. shared an insight ⚡️ 13 hours ago
Zydus Lifesciences Gets Phase III Trial Approval for Desidustat in Sickle Cell Disease.
ZYDUSLIFE
has received approval to initiate the Phase III clinical trial of its oral drug Desidustat for treating Sickle Cell Disease patients. The trial will be conducted in collaboration with the Indian Council of Medical Research (ICMR).
The decision follows the successful completion of the Phase II trial, where Desidustat met its primary endpoints, demonstrating promising efficacy and safety in patients.
Desidustat has also received Orphan Drug Designation from the US FDA, underscoring its potential to address this rare and debilitating blood disorder.
This development marks a significant milestone in Zydus’ efforts to provide an effective oral treatment option for Sickle Cell Disease, which predominantly affects tribal and marginalized populations in India. The advancement is expected to strengthen the company’s presence in the rare disease and specialty therapy segments. shared an insight ⚡️ 16 hours ago
TIPSMUSIC
Reiterates 20% Revenue & PAT Growth Guidance for FYTIPSMUSIC
has reaffirmed its robust growth outlook, maintaining a 20% revenue and Profit After Tax (PAT) growth guidance for the current fiscal year. The company expects annual EBITDA margins to remain healthy in the 65-70% range, though quarterly margins may fluctuate due to content release timings.
Management has allocated an annual content budget of INR 90-100 crore, with a long-term target of 20-25% of revenue. The company also reiterated its commitment to return last year’s PAT of INR 217 crore to shareholders through dividends and buybacks. Despite industry-wide single-digit growth expectations, Tips Music remains confident in achieving its 20% target, backed by strong upcoming content releases and a powerful music catalog.FAQ's
What are the top stock recommendations by CA Sumit Mangla?
CA Sumit Mangla regularly shares stock views and market analysis on StockGro. Some of the stocks they have recently shared views on include Dalmia Bharat Ltd (Bullish), Hindalco Industries Ltd (Bullish), INDUSINDBK, ZYDUSLIFE and TIPSMUSIC. Explore CA Sumit Mangla's complete list of posts and trade views on their StockGro profile.
How can I follow CA Sumit Mangla's latest investment insights?
You can follow CA Sumit Mangla's latest investment insights, stock recommendations, and market analysis on StockGro App. Additionally, you can check their detailed stock analysis reports in the StockGro blog section.
What is CA Sumit Mangla's investment strategy?
CA Sumit Mangla follows a data-driven, research-backed investment strategy focused on maximizing returns while managing risk. Their approach includes fundamental and technical analysis, portfolio diversification, and sectoral trends to identify high-potential stocks.
How long has CA Sumit Mangla been a SEBI-registered Research Analyst (RA)?
CA Sumit Mangla has been a SEBI-registered Research Analyst and have 7+ Years of experience. With extensive experience in stock market analysis and investment research, they have guided investors in making informed and profitable decisions.
Where can I see CA Sumit Mangla's past performance and stock picks?
You can check CA Sumit Mangla's past stock recommendations, success rate, and investment insights on their StockGro profile. Their historical stock picks reflect a track record of strategic investment decisions based on thorough research.
How can I contact CA Sumit Mangla for stock market advice?
For stock market guidance from CA Sumit Mangla, you can connect through their StockGro profile. Some RAs may also provide personalized investment consultations based on their availability and SEBI regulations.
What is CA Sumit Mangla's track record in predicting market movements?
CA Sumit Mangla has a proven track record of accurate market analysis and trend predictions. By analyzing economic indicators, market sentiment, and technical charts, they have consistently helped investors make well-timed investment decisions.
What is the SEBI Registration number for CA Sumit Mangla?
CA Sumit Mangla is a SEBI-registered Research Analyst with the SEBI Registration INH000028626. This ensures that their investment recommendations comply with SEBI's regulatory framework for investor protection and financial advisory standards.
Be Financially Free with StockGro